Nxera Pharma Co., Ltd.
SOLTF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $87 | $116 | $122 | $159 |
| - Cash | $32 | $49 | $67 | $60 |
| + Debt | $68 | $74 | $30 | $29 |
| Enterprise Value | $123 | $141 | $85 | $129 |
| Revenue | $29 | $13 | $16 | $18 |
| % Growth | 125.9% | -18% | -12.1% | – |
| Gross Profit | $21 | $10 | $15 | $17 |
| % Margin | 73.6% | 75.7% | 94.1% | 94.7% |
| EBITDA | $0 | -$6 | $3 | $8 |
| % Margin | 0.4% | -44.7% | 20.4% | 46.2% |
| Net Income | -$5 | -$7 | $0 | $1 |
| % Margin | -16.8% | -56.3% | 2.5% | 5.7% |
| EPS Diluted | -53.95 | -87.17 | 4.63 | 12.4 |
| % Growth | 38.1% | -1,982.7% | -62.7% | – |
| Operating Cash Flow | -$8 | -$5 | $10 | $7 |
| Capital Expenditures | -$2 | -$1 | -$0 | -$0 |
| Free Cash Flow | -$9 | -$6 | $10 | $7 |